Oncotarget

Research Papers:

Prognostic value of follistatin-like 3 in human invasive breast cancer

Henrique L. Couto, Marcelo A. Buzelin, Nivaldo H. Toppa, Enrrico Bloise, Alberto J. Wainstein and Fernando M. Reis _

PDF  |  HTML  |  Order a Reprint

Oncotarget. 2017; 8:42189-42197. https://doi.org/10.18632/oncotarget.15026

Metrics: PDF 382 views  |   HTML 643 views  |   ?  


Abstract

Henrique L. Couto1,2, Marcelo A. Buzelin3, Nivaldo H. Toppa4, Enrrico Bloise5, Alberto J. Wainstein2 and Fernando M. Reis1

1Division of Human Reproduction and Department of Obstetrics and Gynecology, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

2Department of Oncology, Hospital Alberto Cavalcanti, Belo Horizonte, Minas Gerais, Brazil

3Instituto Moacyr Junqueira, Belo Horizonte, Minas Gerais, Brazil

4Laboratório Analys Patologia, Belo Horizonte, Minas Gerais, Brazil

5Department of Morphology, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

Correspondence to:

Fernando M. Reis, email: fmreis@ufmg.br

Keywords: FSTL3, FLRG, follistatin, activin, breast cancer

Received: August 20, 2016     Accepted: January 10, 2017     Published: February 02, 2017

ABSTRACT

Follistatin-like 3 (FSTL3) binds and inactivates activin, a growth factor involved with cell growth and differentiation. We have previously shown FSTL3 overexpression in invasive breast cancers, but its clinical relevance remained unexplored. Here we evaluate FSTL3 as a prognostic tool and its relation with clinical and pathological features of breast cancer. A cohort of 154 women diagnosed with invasive breast cancer between 2008 and 2012 was followed up for 5 years. Tumor samples were processed by immunohistochemistry to detect FSTL3 expression in tumor epithelium. FSTL3 expression was classified semiquantitatively and tested for possible correlation with age, menopause status, stage, tumor histological type and grade, estrogen receptor, progesterone receptor, and HER2 expression. Survival plots with Kaplan-Mayer statistics were used to assess whether FSTL3 expression predicted disease-free survival. Our findings show that FSTL3 staining was unrelated to menopausal status, histological type, disease stage, or receptor profile. However, the intensity of FSTL3 immunostaining correlated inversely with tumor size (r = -0.366, p<0.001) and with nuclear grade (p<0.01). The intensity of FSTL3 expression in the tumoral epithelium was not predictive of the disease-free survival (p = 0.991, log-rank test), even though the follow-up length and the study size were sufficient to detect a significant reduction in disease-free survival among women with stage III-IV compared to stage I-II disease (p<0.001). FSTL3 expression in invasive breast cancer is inversely associated with tumor size and nuclear grade but it does not predict disease relapse in the short term.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15026